Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
OBJECTIVES: I. Determine the pathologic complete response rate to docetaxel in patients with
high risk stage II or III prostate cancer. II. Determine the toxicity of this treatment in
these patients. III. Correlate clinical measures of response (e.g., symptoms, physical exam,
serum PSA, and endorectal MRI) with pathologic response to this treatment in these patients.
OUTLINE: Patients receive docetaxel IV over 30 minutes weekly for 4 weeks. Treatment
continues for 2-6 courses in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 19-45 patients will be accrued for this study over 18 months.
Primary Purpose: Treatment
William Oh, MD
Dana-Farber Cancer Institute
United States: Federal Government
|Massachusetts General Hospital Cancer Center||Boston, Massachusetts 02114|
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Brigham and Women's Hospital||Boston, Massachusetts 02115|